The liposome technology provides intelligent solutions to solve challenges in pharmacology such as e.g. increase drug solubility, reduce drug toxicity, improve targeted drug release, etc. Thus, in first aspect the invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A 2 (sPLA 2 ) activity, because phospholipase A 2 (PLA 2 ) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. A second aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.
